QuantumScape Corporation reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, GAAP operating expenses were USD 110.5 million, and the GAAP net loss was USD 100.1 million. The company recorded an Adjusted EBITDA loss of USD 63.3 million in Q4. For the full year 2025, GAAP operating expenses totaled USD 472.6 million, with a GAAP net loss of USD 435.1 million. Adjusted EBITDA loss for FY 2025 was USD 252.3 million, showing an approximately 10 percent year-over-year improvement. Capital expenditures in Q4 were USD 12.3 million and USD 36.3 million for the year. Customer billings for FY 2025 were USD 19.5 million. For 2026, QuantumScape expects full-year Adjusted EBITDA loss to be between USD 250 million and USD 275 million and capital expenditures to range from USD 40 million to USD 60 million. On the business front, QuantumScape achieved all four of its major 2025 objectives, including the integration of its Cobra process into cell production, shipment of Cobra-based QSE-5 cells, installation of equipment for its Eagle Line, and expansion of commercial engagements. The company highlighted significant improvements in the production process for its proprietary ceramic separator, a core component of its solid-state battery technology. Looking ahead, QuantumScape plans to advance its technology roadmap and ramp up production of the QSE-5 platform in 2026. QuantumScape also announced the retirement of co-founder Professor Dr. Fritz Prinz from its board of directors after more than fifteen years of service.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. QuantumScape Corporation published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.